Novo Nordisk's Mounting Headwinds: A Buyback, a Workforce Crisis, and a Stock in the Doldrums
Published on 08/18/2026 at 08:32 | Redaktion boerse-global.de
The Danish pharmaceutical giant is spending billions on its own shares, yet the market remains singularly unimpressed. Novo Nordisk disclosed on Monday that it has plowed roughly 8.08 billion Danish kroner into its ongoing buyback program, snapping up 28,884,179 B-shares at an average price of 279.80 kroner through August 14. The twelve-month scheme, which kicked off on February 4, is capped at 15 billion kroner, and the company now holds 42,924,876 treasury shares—equivalent to one percent of its share capital.
The relentless repurchase activity, however, is doing little to arrest the slide in the company's valuation. In German trading, the stock closed Monday at 38.84 euros, down 1.4 percent on the day, and has shed 11 percent over the past month. The shares now sit 3.5 percent below their 200-day moving average, a technical signal that has investors questioning whether the buyback is merely a floor that keeps failing to hold.
A CEO Steps Into the Fray
The financial pressures are compounded by an unusually public internal crisis. CEO Mike Doustdar took to LinkedIn on Monday to address mounting criticism over his leadership style and the company's workplace culture—a rare move for a chief executive who typically communicates through official channels. The direct engagement comes in response to sharp rebukes from unions and a former workplace stress ombudsman, and it underscores just how combustible the situation has become.
Workplace culture disputes rarely stay internal for long, and when they spill into public view, the scrutiny on your safety and HR practices intensifies. Having proper documentation ready can make all the difference when regulators or unions come asking questions. A free toolkit with 41 ready-to-use templates and checklists helps you demonstrate compliance with confidence. Download the free Risk Assessment Toolkit
At the heart of the dispute is the largest workforce reduction in Danish corporate history: roughly 5,000 job cuts are on the table. Works councils are scrambling to limit the scale of the layoffs, while union leaders such as Sara Vergo, chair of the Djøf union, are pushing for solid re-employment prospects for affected members. Danish commentators note that the domestic C25 index has managed only a 4.1 percent gain this year—lagging well behind European and American benchmarks—largely due to Novo Nordisk's underperformance.
Pipeline Disappointments Pile Up
The personnel turmoil arrives at a moment when the company's scientific narrative is also fraying. Disappointing results from the ZEUS study, released roughly two weeks ago, have knocked 2.7 percent off the share price. While the drug candidate ziltivekimab hit its target structure and lowered inflammatory markers, it failed to demonstrate a reduction in major cardiovascular events compared to placebo. The company has consequently flagged a non-cash impairment charge for the third quarter, though it insists the 2026 earnings guidance remains unaffected.
The CagriSema pipeline has also been a source of disillusionment, with related study data emerging around the same timeframe and dragging the stock down 2.6 percent. Adding to the legal overhang, a US federal judge recently allowed portions of a securities lawsuit to proceed, specifically allegations concerning misleading statements tied to the REDEFINE 1 study.
Competition Heats Up in the Oral Obesity Arena
The competitive landscape is shifting beneath Novo Nordisk's feet. Analysts at Berenberg downgraded the stock on August 12 from Buy to Hold, trimming their price target to 47 US dollars from 50. The bank cited intensifying rivalry in the oral weight-loss segment, particularly from Eli Lilly's Foundayo. Berenberg noted that the "easy gains" from the original thesis around the Wegovy pill have already been realized. BMO Capital reaffirmed its Hold rating the same day, and the DZ Bank issued a similar assessment on August 7.
A more concrete threat looms on October 1, when CVS Caremark—a pharmacy benefit manager commanding roughly 26 percent of the US market—will add additional weight-loss drugs to its largest commercial formularies. This ends the exclusive positioning Novo Nordisk secured with the provider in July 2025, a development the company itself disclosed during its half-year results.
The Pill That Still Works
Amid the gloom, one bright spot persists. The Wegovy pill has generated more than five million cumulative prescriptions since its January launch and commands a 90 percent share of the US oral obesity market. Whether that dominance survives the intensifying competition and the impending formulary changes is the question that will define the coming months.
When a company's internal turmoil becomes front-page news, it's a reminder that workplace safety and compliance documentation can never be an afterthought. Over 37,000 UK businesses use a free toolkit with risk assessments, checklists, and toolbox talks to stay aligned with current regulations. Get the free Health & Safety Toolkit
For now, the stock trades 29 percent below its late-January 52-week high, a stark measure of how far investor confidence has fallen. The buyback continues apace, the CEO is fighting fires on social media, and the market is watching to see whether the workforce question becomes an independent risk factor that complicates any operational recovery.
